So-called 'analysts' on the Street (emphasis on 1st two syllables!) shouldn't even try to write about biotech or pharma -- they're much too ignorant. Like this:
"Isis announced Tuesday that its experimental antisense drug ISIS-PTP1B Rx achieved statistically significant reductions in hemoglobin and body weight in patients with Type 2 diabetes when compared with a placebo at 36 weeks in a Phase II study.
But the company designed the study to determine changes in hemoglobin and body weight at 27 weeks, according to ClinicalTrials.gov. Isis did not disclose the effect of its diabetes drug at 27 weeks."
"Reduction in hemoglobin"? Seriously? Anybody need to cause anemia anywhere?
The second paragraph shows the author probably believes in black helicopters.
Biotech investing is quite risky enough without such idiots creating meaningless short-term volatility.